ArticleBone marrow transplantation2016
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients.
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.Clinical lymphoma, myeloma & leukemia · 2020Pooled it
- Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.Annals of hematology · 2025Review
- Steps towards a Multiple Myeloma Cure?Journal of personalized medicine · 2022Article
- Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?British journal of haematology · 2020Review
- Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.Journal of personalized medicine · 2020Review
- Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2019Article
- Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.Bone marrow transplantation · 2018Article
- Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26926231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.